Tagged with Takeda

Egypt Takeda Egypt’s Samy Khalil gives an overview of the company’s presence in the country and the fundamentals behind its double-digit growth there, provides his view of the healthcare transformation of the country – both achievements and challenges – and explains why Egypt was added to Takeda’s Access Markets cluster.  …

Indonesia Takeda gets a first approval for QDENGA, its dengue vaccine, which has been given the green light by the Indonesian National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), making it the only dengue vaccine approved in the country for use in individuals aged 6 to…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar, and Takeda’s investment in an IT centre in the Slovak capital, Bratislava. Elsewhere, Pfizer has begun construction on a new…

Switzerland After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment from Takeda. “Switzerland is a globally recognized hotspot for biopharma companies. As such, it naturally attracts investments. Our role is…

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

Japan A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for its Niemann-Pick types A/B and B medicine in Japan, and the prospect of domestically developed COVID-19 vaccines being rolled out…

USA Ramona Sequeira, recently appointed chair of the PhRMA board of directors and president of Takeda’s US Business Unit and Global Portfolio Commercialization, gives her take on how the biopharma industry can do more to address the systemic inequities in US healthcare, including community-focused grant programs, clinical trial diversity initiatives, and…

USA Ramona Sequeira of Takeda has taken the reins as chair of US industry lobby group PhRMA’s Board of Directors, becoming the first ever woman to hold the role. She succeeds Lilly Chairman and CEO David Ricks at a juncture when the industry is under pressure from proposed US pricing reforms…

MEA The top 10 fastest growing pharma companies in the Middle East and Africa (region) ranked by previous period growth between MAT Q2 2020 and MAT Q2 2021. The list is dominated by regional players including Julphar, Sedico/Acdima and Eva Pharma, but multinational firms are also represented by Gilead Sciences, Takeda,…

Asia-Pacific To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC has identified six key trends for emerging biotechs to watch. For a full interview with Senthil Sockalingam, head of IQVIA…

Global The oncology field has exploded in the past 20 years and pharma companies now have a wide range of approaches available to them as they look to identify, treat, and in some cases even cure, cancer patients. Here, five industry experts weigh in on the exciting new tools and technology…

MENA The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma multinationals explain what MEA means to their global groups and their key areas of focus today.   Biogen: Awareness is…